Noda Naotaka, Matsuzoe Daisuke, Konno Toshikazu, Kawahara Katsunobu, Yamashita Yuichi, Shirakusa Takayuki
Second Department of Surgery, Fukuoka University School of Medicine, Fukuoka City, Fukuoka 814-0180, Japan.
Oncol Rep. 2004 Oct;12(4):773-9.
Polycyclic aromatic hydrocarbons (PAHs) and other tobacco-related carcinogens are oxidized by phase I enzymes into reactive metabolites that are then detoxified by phase II enzymes. These findings suggested that polymorphisms in genes controlling metabolism of carcinogens underlie individual variations in cancer susceptibility. Moreover, it is unclear whether there is a relation between genetically determined individual susceptibilities and target gene mutations in lung carcinogenesis. We examined K-ras mutations in relation to polymorphisms in the cytochrome P4501A1 (CYP1A1) and glutathione S-transferase micro1 (GSTM1) genes in 246 patients with lung adenocarcinoma and 167 patients with lung squamous cell carcinoma. K-ras mutations were found in 33 of 413 (8.0%) tumors, and all K-ras gene mutations were found in habitual smokers, 110 non-smokers were excluded from final analysis. Among smokers with lung adenocarcinoma, K-ras mutations occurred with greater frequency in patients with the GSTM1(-) genotype than in those with the GSTM1(+) genotype. Patients with a combination of the CYP1A1 m1/m2 and GSTM1(-) genotypes showed an increased probability of having mutated K-ras genes (OR, 6.00; p=0.031; 95% CI, 1.18-30.62) in comparison to those with the CYP1A1 m1/m1 and GSTM1(+) genotypes. The impact of combined genotypes of the CYP1A1 Ile/Val polymorphism and GSTM1 on mutation of K-ras was also analyzed, and a higher risk of having a mutated K-ras gene was found for both the CYP1A1 Ile/Ile and GSTM1(-) (OR, 6.32; p=0.021; 95% CI, 1.33-30.19) and CYP1A1 Ile/Val and GSTM1(-) (OR, 6.09; p=0.042; 95% CI, 1.07-34.72) genotype combinations in patients with adenocarcinoma. There was no significant association for squamous cell carcinoma. In conclusion, these findings suggest that K-ras mutations in smokers with lung adenocarcinoma may be due in part to accumulation of carcinogens, which is not adequately detoxified in individuals with certain CYP1A1 genotypes and the GSTM1(-) genotype.
多环芳烃(PAHs)及其他与烟草相关的致癌物会被I相酶氧化为活性代谢产物,然后由II相酶进行解毒。这些发现表明,控制致癌物代谢的基因多态性是癌症易感性个体差异的基础。此外,在肺癌发生过程中,基因决定的个体易感性与靶基因突变之间是否存在关联尚不清楚。我们在246例肺腺癌患者和167例肺鳞状细胞癌患者中,研究了K-ras突变与细胞色素P4501A1(CYP1A1)和谷胱甘肽S-转移酶微1(GSTM1)基因多态性的关系。在413个肿瘤中有33个(8.0%)发现了K-ras突变,所有K-ras基因突变均在习惯性吸烟者中发现,110名非吸烟者被排除在最终分析之外。在肺腺癌吸烟者中,GSTM1(-)基因型患者的K-ras突变发生率高于GSTM1(+)基因型患者。与CYP1A1 m1/m1和GSTM1(+)基因型患者相比,CYP1A1 m1/m2和GSTM1(-)基因型组合的患者发生K-ras基因突变的概率增加(比值比,6.00;p = 0.031;95%可信区间,1.18 - 30.62)。还分析了CYP1A1 Ile/Val多态性和GSTM1的联合基因型对K-ras突变的影响,发现肺腺癌患者中CYP1A1 Ile/Ile和GSTM1(-)(比值比,6.32;p = 0.021;95%可信区间,1.33 - 30.19)以及CYP1A1 Ile/Val和GSTM1(-)(比值比,6.09;p = 0.042;95%可信区间,1.07 - 34.72)基因型组合发生K-ras基因突变的风险更高。肺鳞状细胞癌患者中无显著关联。总之,这些发现表明,肺腺癌吸烟者中的K-ras突变可能部分归因于致癌物的积累,而在某些CYP1A1基因型和GSTM1(-)基因型个体中,致癌物未得到充分解毒。